Broadly reactive antibodies specific for Plasmodium falciparum MSP-119 are associated with the protection of naturally exposed children against infection
暂无分享,去创建一个
J. Vulule | J. Kazura | B. Crabb | A. Moormann | C. Long | D. Tisch | A. Dent | Rhonda J. Kimmel | D. Narum | C. Yohn | P. O. Sumba
[1] J. Kazura,et al. Broadly reactive antibodies specific for Plasmodium falciparum MSP-119 are associated with the protection of naturally exposed children against infection , 2012, Malaria Journal.
[2] N. D. Djadid,et al. Non-variant specific antibody responses to the C-terminal region of merozoite surface protein-1 of Plasmodium falciparum (PfMSP-119) in Iranians exposed to unstable malaria transmission , 2010, Malaria Journal.
[3] I. Mueller,et al. Treatment with coartem (artemether-lumefantrine) in Papua New Guinea. , 2010, The American journal of tropical medicine and hygiene.
[4] Jack S. Richards,et al. The Relationship between Anti-merozoite Antibodies and Incidence of Plasmodium falciparum Malaria: A Systematic Review and Meta-analysis , 2010, PLoS medicine.
[5] A. Djimde,et al. Understanding the pharmacokinetics of Coartem® , 2009, Malaria Journal.
[6] J. Kazura,et al. Temporal stability of naturally acquired immunity to Merozoite Surface Protein-1 in Kenyan Adults , 2009, Malaria Journal.
[7] R. Ploutz-Snyder,et al. Serological evidence for long‐term epstein–barr virus reactivation in children living in a holoendemic malaria region of Kenya , 2009, Journal of medical virology.
[8] V. A. Stewart,et al. Blood Stage Malaria Vaccine Eliciting High Antigen-Specific Antibody Concentrations Confers No Protection to Young Children in Western Kenya , 2009, PloS one.
[9] P. Gilson,et al. Immunoglobulin G Subclass-Specific Responses against Plasmodium falciparum Merozoite Antigens Are Associated with Control of Parasitemia and Protection from Symptomatic Illness , 2009, Infection and Immunity.
[10] M. Lebbad,et al. Extensive dynamics of Plasmodium falciparum densities, stages and genotyping profiles , 2008, Malaria Journal.
[11] R. Chilengi,et al. Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian children , 2008, Malaria Journal.
[12] John J. Erickson,et al. Monitoring Plasmodium falciparum growth and development by UV flow cytometry using an optimized Hoechst‐thiazole orange staining strategy , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[13] D. Conway,et al. Breadth and Magnitude of Antibody Responses to Multiple Plasmodium falciparum Merozoite Antigens Are Associated with Protection from Clinical Malaria , 2008, Infection and Immunity.
[14] J. Soto,et al. Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study. , 2008, The American journal of tropical medicine and hygiene.
[15] J. Vulule,et al. A polymerase chain reaction/ligase detection reaction fluorescent microsphere assay to determine Plasmodium falciparum MSP-119 haplotypes. , 2007, The American journal of tropical medicine and hygiene.
[16] David L. Smith,et al. Dynamics of Polymorphism in a Malaria Vaccine Antigen at a Vaccine-Testing Site in Mali , 2007, PLoS medicine.
[17] J. Kazura,et al. Prenatal Malaria Immune Experience Affects Acquisition of Plasmodium falciparum Merozoite Surface Protein-1 Invasion Inhibitory Antibodies during Infancy1 , 2006, The Journal of Immunology.
[18] G. Fouda,et al. Multiplex Assay for Simultaneous Measurement of Antibodies to Multiple Plasmodium falciparum Antigens , 2006, Clinical and Vaccine Immunology.
[19] Hong Zhou,et al. Immunity to Recombinant Plasmodium falciparum Merozoite Surface Protein 1 (MSP1): Protection in Aotus nancymai Monkeys Strongly Correlates with Anti-MSP1 Antibody Titer and In Vitro Parasite-Inhibitory Activity , 2006, Infection and Immunity.
[20] M. Schluchter,et al. Correlation of high levels of antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens and protection from infection. , 2005, The American journal of tropical medicine and hygiene.
[21] C. John,et al. Evidence That Invasion-Inhibitory Antibodies Specific for the 19-kDa Fragment of Merozoite Surface Protein-1 (MSP-119) Can Play a Protective Role against Blood-Stage Plasmodium falciparum Infection in Individuals in a Malaria Endemic Area of Africa1 , 2004, The Journal of Immunology.
[22] A. Holder,et al. Fine Specificity of Serum Antibodies to Plasmodium falciparum Merozoite Surface Protein, PfMSP-119, Predicts Protection from Malaria Infection and High-Density Parasitemia , 2004, Infection and Immunity.
[23] S. Howell,et al. A Single Malaria Merozoite Serine Protease Mediates Shedding of Multiple Surface Proteins by Juxtamembrane Cleavage* , 2003, Journal of Biological Chemistry.
[24] A. P. Tonon,et al. Sequence diversity and evolution of the malaria vaccine candidate merozoite surface protein-1 (MSP-1) of Plasmodium falciparum. , 2003, Gene.
[25] I. Bygbjerg,et al. Diversity of Plasmodium falciparum clones infecting children living in a holoendemic area in north-eastern Tanzania. , 2002, Acta tropica.
[26] A. Holder,et al. The Human Immune Response to Plasmodium falciparum Includes Both Antibodies That Inhibit Merozoite Surface Protein 1 Secondary Processing and Blocking Antibodies , 2002, Infection and Immunity.
[27] M. D. Wilson,et al. Novel Plasmodium falciparum clones and rising clone multiplicities are associated with the increase in malaria morbidity in Ghanaian children during the transition into the high transmission season , 2001, Parasitology.
[28] A. Cowman,et al. Antibodies against Merozoite Surface Protein (Msp)-119 Are a Major Component of the Invasion-Inhibitory Response in Individuals Immune to Malaria , 2001, The Journal of experimental medicine.
[29] A. Hill,et al. Identification of frequently recognized dimorphic T-cell epitopes in plasmodium falciparum merozoite surface protein-1 in West and East Africans: lack of correlation of immune recognition and allelic prevalence. , 2001, The American journal of tropical medicine and hygiene.
[30] M. Alpers,et al. Genetic diversity and dynamics of Plasmodium falciparum and P. vivax populations in multiply infected children with asymptomatic malaria infections in Papua New Guinea , 2000, Parasitology.
[31] M. Blackman,et al. Proteases involved in erythrocyte invasion by the malaria parasite: function and potential as chemotherapeutic targets. , 2000, Current drug targets.
[32] D. Conway,et al. A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses , 2000, Nature Medicine.
[33] D. Conway,et al. Allelic recombination and linkage disequilibrium within Msp-1 of Plasmodium falciparum, the malignant human malaria parasite. , 1999, Gene.
[34] Thomas A. Smith,et al. 6. Multiple Plasmodium falciparum infections in Tanzanian infants , 1999 .
[35] M Tanner,et al. Multiple Plasmodium falciparum infections in Tanzanian infants. , 1999, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[36] B. Nahlen,et al. Predicted and observed alleles of Plasmodium falciparum merozoite surface protein-1 (MSP-1), a potential malaria vaccine antigen. , 1998, Molecular and biochemical parasitology.
[37] O. Branch,et al. A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kiloDalton domain of Plasmodium falciparum in pregnant women and infants: associations with febrile illness, parasitemia, and anemia. , 1998, The American journal of tropical medicine and hygiene.
[38] O. Kaneko,et al. Plasmodium falciparum: allelic variation in the merozoite surface protein 1 gene in wild isolates from southern Vietnam. , 1997, Experimental parasitology.
[39] G. Snounou,et al. Daily dynamics of Plasmodium falciparum subpopulations in asymptomatic children in a holoendemic area. , 1997, The American journal of tropical medicine and hygiene.
[40] A. Holder,et al. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. , 1996, The Journal of infectious diseases.
[41] C. Long,et al. Sequence heterogeneity of the C-terminal, Cys-rich region of the merozoite surface protein-1 (MSP-1) in field samples of Plasmodium falciparum. , 1995, Molecular and biochemical parasitology.
[42] O. Branch,et al. Identification of T and B cell epitopes recognized by humans in the C-terminal 42-kDa domain of the Plasmodium falciparum merozoite surface protein (MSP)-1. , 1995, Journal of immunology.
[43] A. Holder,et al. Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein , 1994, The Journal of experimental medicine.
[44] D. Kaslow,et al. Expression and antigenicity of Plasmodium falciparum major merozoite surface protein (MSP1(19)) variants secreted from Saccharomyces cerevisiae. , 1994, Molecular and biochemical parasitology.
[45] P. Barr,et al. Immunological cross-reactivity of the C-terminal 42-kilodalton fragment of Plasmodium falciparum merozoite surface protein 1 expressed in baculovirus , 1993, Infection and immunity.
[46] P. Barr,et al. A carboxyl-terminal fragment of Plasmodium falciparum gp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth. , 1992, Journal of immunology.
[47] A. Holder,et al. A malaria merozoite surface protein (MSP1)-structure, processing and function. , 1992, Memorias do Instituto Oswaldo Cruz.